Define the treatment patterns and associated costs to treat metastatic prostate cancer in Brazilian private health care system. METHODS: In a nationwide oncology claims database of 3.5 million lives, from August 2010 to July 2011, 67 patients were identified with metastatic prostate cancer using chemotherapy. Patients using hormone therapy were excluded. The database gathered information regarding the treatment patients were submitted, to average duration and medication dosage. RESULTS: Patients were on average 71 years old, weighted 78 kilograms and measured 1.70 meters. Among the 67 patients, only 5 (7%) were submitted to first line treatment with mitoxantrone and 62 (93%) with docetaxel; 58% of all patients took a second line treatment. From the 62 patients that started with docetaxel (121.5 mg average dose for each of the 6.5 cycles (21days)), 28 had a second line treatment with mitoxantrone (20mg average dose for each of the 3.9 cycles (21days)) with total average cost/patient of R$ 39,698 (USD 22,056); 7 were retreated with docetaxel (60mg average dose for each of the 6 cycles (7days)). From the 5 patients that started with mitoxantrone (20.6mg average dose for each of the 3.2 cycles (21 days)), 4 continued the treatment with docetaxel (60mg average dose for each of the 3 applications (21 days)) with a total average cost/patient of R$ 12,795 (USD 7,107). CONCLUSIONS: The database suggests that docetaxel is the most commonly used first line treatment to metastatic prostate cancer in the Brazilian private health care system. Forty-two percent of the patients were not submitted to a second pattern in the period studied, being that 18% of the ones that had a second line treatment were retreated with the same medication (docetaxel). 
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PATTERNS OF CARE AND COSTS ASSOCIATED WITH TREATMENT OF PATIENTS WITH BONE METASTASES SECONDARY TO PROSTATE CANCER
Analysis by Design LLC, Columbia, MD, USA OBJECTIVES: Treatment of bone metastases secondary to prostate cancer typically involves different provider types and a combination of surgery, radiation, and pharmaceutical treatment. This study evaluated treatment patterns and costs for patients with bone metastases secondary to prostate cancer. Which providers had patients with bone metts that increased costs in surgery, radiation and chemotherapy compared to no bone metts? METHODS: Continuously enrolled patients in the MarketScan database between January 2004 and December 2010 with evidence of bone metastases (ICD9 code 198.5 or treatment with one of the following medications: zolderonic acid, pamidronate, or demosumab) were included. The relationship between patterns of care regarding physician specialty, type of therapy and cost of treatment were assessed. RESULTS: Total of 4493 patients had evidence of bone metastases. Most patients (nϭ2633, 59%) had both an urologist and a radiologist involved in their care. Common combinations of providers were urologist and radiologist (U&R, 22%); urologist, radiologist, and surgeon (U, R&S, 21%), and urologist, radiologist, and oncologist (U, R&O, 17%). A majority of patient were prescribed hormone therapy (89%) and 76% were prescribed steroid agents (mostly glucocorticoids). Half of the population received radiation therapy (nϭ2274, 51%) and 1,838 (41%) received surgery related to their prostate cancer. Significant differences in total cost, depending on the mix of specialists involved in care: U&R: $22,133; U, R&S: $28,305; and U, R&O: $34,366 (pϽ0.001 for all pairwise comparisons). Common treatment combinations were also associated with significantly different total costs: patients receiving steroids, radiation, chemotherapy, and hormone treatment cost the most (mean: $47,914) while patients steroids, surgery, chemotherapy, and hormone therapy cost the least (mean: $31,612). CONCLUSIONS: Significant variation in patterns of care and total costs for patients who have bone metastases secondary to prostate cancer. Additional studies should examine the potential drivers of this variation and strategies to maximize costeffectiveness. 4) were included. Patients were required to be Ն40 years of age with no additional cancers. Utilization of PCa-specific treatments and costs across relevant inpatient cost centers were assessed and described. RESULTS: There were 88,151 hospitalizations of men treated for PCa in an inpatient setting. The mean age of the sample was 69 years, with 68% being Caucasian. The average hospitalization cost was $12,286 for 4 days of stay. The most common treatments provided were surgery (57%), miscellaneous drug therapy (39%), hormone therapy (30%), and radiation treatment (4%). Accordingly, approximately 26% of costs were associated with surgery, and 31% were associated with room and board; pharmaceuticals accounted for 8% of costs. CONCLUSIONS: Men treated for PCa in an inpatient setting averaged $4516 per day for approximately 4 days, with surgery and miscellaneous drug therapy being the most frequently used inpatient treatments. OBJECTIVES: This study examined total health care expenditures in newly diagnosed subjects with colorectal cancer (CRC) over time and by lines of therapy received. METHODS: Patients aged 18-years and older when newly diagnosed with CRC between January 1, 2005 and June 31, 2009 were identified using a large, USbased administrative medical claims (MarketScan) database. Patients were identified with CRC if they had an ICD-9-CM claim for a primary diagnosis of colon or rectal cancer on 2 different days but within 180 days of each other. At least 6 months of patient history prior to CRC diagnosis and at least 1-year post-index continuous enrollment was required. Patients were followed from initial CRC diagnosis (index date) to disenrollment or June 31, 2010. Chemotherapy and biologic treatments over time were analyzed to identify lines of therapy. Total health care costs included costs associated with CRC and other comorbidities. Univariate analyses were performed to examine changes in costs over time and with increasing lines of therapy. RESULTS: A total of 23,547 subjects were included with a mean age of 65.3 years, 49% were over 65 years, and 52% were males. They were predominately from the South (40%) and the Midwest region (36%) and majority (54%) were enrolled in a preferred provider organization plan. 63% of the subjects received no systemic treatment for CRC and 17%, 13%, and 7% received 1 
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